Nuveen Asset Management LLC Decreases Holdings in Harrow, Inc. (NASDAQ:HROW)

Nuveen Asset Management LLC trimmed its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 65.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 113,752 shares of the company’s stock after selling 215,172 shares during the quarter. Nuveen Asset Management LLC owned 0.32% of Harrow worth $3,816,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Woodmont Investment Counsel LLC raised its position in shares of Harrow by 0.5% during the 4th quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company’s stock valued at $2,731,000 after buying an additional 445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Harrow by 3.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company’s stock valued at $582,000 after purchasing an additional 585 shares during the last quarter. Swiss National Bank grew its holdings in Harrow by 1.0% during the 4th quarter. Swiss National Bank now owns 59,300 shares of the company’s stock valued at $1,990,000 after purchasing an additional 600 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Harrow by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after purchasing an additional 727 shares during the last quarter. Finally, MetLife Investment Management LLC grew its holdings in Harrow by 5.7% during the 4th quarter. MetLife Investment Management LLC now owns 18,908 shares of the company’s stock valued at $634,000 after purchasing an additional 1,026 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Price Performance

Shares of HROW stock opened at $28.24 on Monday. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The company has a market capitalization of $1.04 billion, a P/E ratio of -30.04 and a beta of 0.41. The company’s 50-day simple moving average is $25.18 and its two-hundred day simple moving average is $30.30. Harrow, Inc. has a one year low of $16.71 and a one year high of $59.23.

Harrow (NASDAQ:HROW) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. As a group, equities analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on HROW. HC Wainwright upped their price target on shares of Harrow from $57.00 to $60.00 and gave the company a “buy” rating in a report on Monday, May 12th. B. Riley cut their price target on shares of Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.